© Immago Biosystems Ltd 2015

Home Science Technology Partnerships About Us




Immago is developing innovations in the field of therapeutic antibodies arising from work in the Glycobiology Institute of the University of Oxford.

With our technology we seek to enable a new generation of cancer therapies by enhancing the efficacy of therapeutic monoclonal antibodies (mAbs).

Working with partners, we aim to develop better anti-cancer therapies, by improving the efficacy of existing and abandoned mAbs, and developing novel mAbs taking advantage of our unique knowledge of the field of therapeutic glycoproteins.


Introducing Immago Biosystems